

NZX/ASX Announcement

7/04/2025

Changes to US and China Tariff Regimes have no impact on TruScreen

- **TruScreen's unique AI enabled cervical cancer screening device is not impacted by changes to the US and China proposed tariff regimes**
- **Focus on emerging markets ensures TruScreen sales are unaffected by increased tariffs on Australian products entering the USA**
- **TruScreen markets both an Australian and a Made in China device providing a dual product strategy in the key China market, with preferential market access for China manufactured products**
- **China proposed retaliatory 34% tariff on US made products entering China strengthen TruScreen's domestic manufactured advantage**

TruScreen Group Limited ("TruScreen" or "the Company") advises that its unique AI enabled cervical cancer screening device is not impacted by changes to the US and China proposed tariff regimes.

TruScreen has pursued an emerging markets strategy. The United States is currently not a distribution territory or strategic focus for TruScreen.

The TruScreen device is a particularly appropriate primary cervical cancer screening tool in regions with high mortality to cervical cancer. TruScreen's growth strategy focuses on emerging markets, especially China, and Low and Middle Income Countries (LMICs) such as India, Indonesia, Mexico, Vietnam, Uzbekistan and Zimbabwe.

TruScreen manufactures both an Australian and a Chinese made device. This strategy de-risks government policy changes in the key China market, where there is a preferential purchasing policy for China manufactured products.

The announcement that China proposes to impose a retaliatory 34% tariff on US made products into China will strengthen TruScreen's Made in China competitive advantage over imported US manufactured cytology (pap smear) and HPV DNA products.

This announcement has been approved by the Board.

Ends

For more information, visit www.truscreen.com or contact:

Martin Dillon
Chief Executive Officer
martindillon@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China. TruScreen currently does not distribute its medical device in the USA.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"®.

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

Glossary:

Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a microscope. <https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/pap-test>

LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at the same time, such as the human papillomavirus (HPV) test <https://www.cancer.net/cancer-types/cervical-cancer/diagnosis>

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done on a sample of cells which a person can collect on their own. <https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention>

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

- **Sensitivity** (true positive rate) is the probability of a positive test result, [conditioned](#) on the individual truly being positive.
- **Specificity** (true negative rate) is the probability of a negative test result, conditioned on the individual truly being negative ([Sensitivity and specificity – Wikipedia](#)).

For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia, please see useful links:

New Zealand: [National Cervical Screening Programme | National Screening Unit \(nsu.govt.nz\)](#)

Australia: [Cervical cancer | Causes, Symptoms & Treatments | Cancer Council](#)